Tixagevimab with cilgavimab (Evusheld) Access Criteria

Availability of Evusheld

With the criteria on this page, tixagevimab with cilgavimab is available through:

  • Te Whatu Ora – Health New Zealand hospitals
  • primary care providers in the community.

Pharmac has secured supply of 20,000 300 mg courses of tixagevimab with cilgavimab. Since we initially consulted on the access criteria, AstraZenaca (the supplier) has increased the recommended dose from 300 mg to 600 mg (unapproved dose). As a result we have set the criteria to reflect that we only have 10,000 doses available.

Community supply

Tixagevimab with cilgavimab has been available for use in the community from primary care providers since 3 October 2022.

Stock is available for ordering by community pharmacies directly from Healthcare Logistics (HCL).

The community roll-out for tixagevimab with cilgavimab is being led by Te Whatu Ora. Further details of the ordering and administration process is provided in this document from the Ministry of Health(external link).

Further detail of the fees and claiming process for the administration of tixagevimab with cilgavimab in primary care can be requested from your primary health organisations or district portfolio manager.

Tixagevimab with cilgavimab access criteria

Indication – Pre-exposure prophylaxis

Access criteria - Any relevant practitioner. 

Approvals are valid for patients where the prescribing clinician confirms the patient meets the following criteria and has endorsed the prescription accordingly: 

All of the following: 

Notes:

* potent B-cell or T-cell depleting therapy such as rituximab, obinutuzumab, ocrelizumab, bendamustine, fludarabine, cladribine, alemtuzumab, anti-thymocyte globulin, CamPath antibody treatment, anti-B-cell bispecific antibody, CAR T-cells or BiTE antibody treatment 

Funded dosing:

  • Medsafe has provisionally approved Evusheld for pre-exposure prophylaxis at a dose of 300mg IM (150mg tixagevimab and 150mg cilgavimab).
  • Maximum funded single dose of 600mg IM (300mg tixagevimab and 300 mg cilgavimab) permitted. This dose is not approved by Medsafe.
  • Repeat dosing is not currently funded.